Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
March 25, 2019 00:00 ET
|
Dermira, Inc.
New multichannel consumer campaign will feature QBREXZA patientsCampaign to drive consumer awareness of QBREXZAQBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment...
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 22, 2019 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Prices $130.0 Million Public Offering of Common Stock
March 19, 2019 19:36 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Proposed Public Offering of Common Stock
March 18, 2019 16:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
March 18, 2019 07:00 ET
|
Dermira, Inc.
- All three doses of lebrikizumab met primary endpoint with statistical significance- Lebrikizumab was well-tolerated; safety profile consistent with prior studies- Efficacy and safety profile support...
Dermira to Present at the Cowen and Company 39th Annual Health Care Conference
March 05, 2019 16:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis
March 01, 2019 08:00 ET
|
Dermira, Inc.
Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis New analysis from...
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
February 26, 2019 16:01 ET
|
Dermira, Inc.
QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 millionOver 14,500 prescriptions for QBREXZA written in first three months of launchSecured QBREXZA coverage for approximately 76% of...
Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting
February 26, 2019 08:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis
February 22, 2019 08:00 ET
|
Dermira, Inc.
- Study will assess the impact of QBREXZA treatment on sweat severity in patients with primary palmar hyperhidrosis- Results will inform potential development plans for QBREXZA in primary palmar...